The Saudi Food & Drug Authority (SFDA) has announced the withdrawal and suspension of registration of Omiz Plus 40/1100mg Capsule with registration number (244-277-12), and Omiz Plus 20/1100 mg Capsule with registration number (245-277-12).

SFDA added that, the medicines produced by Tabuk Pharmaceuticals.  

It has decided to withdraw and suspend its registration due to the medicine’s non-bio equivalence to the reference product.

The Authority addressed health authorities and company to withdraw the medicines as soon as it is available, calling on the medicine users to contact their doctors to receive the alternative medication.

The Authority’s circular is based on the decision of the registration of pharmaceutical companies and their products Committee (No 18/1061/sfda/42), to suspend the registration and withdrawal the product.